Exclusive Summary

• Dual Regulatory Validation: Successfully obtained IND approval from the US FDA and is currently in Phase I Clinical trials in China, demonstrating high regulatory compliance for global markets.
• Superior Safety & Manufacturing: Claims advantages over competitors with lower mortality from Cytokine Release Syndrome (CRS), reduced neurotoxicity, and a lower preparation failure rate via an automated platform.
• Pioneering Potential: Positioned as the "world's first" CD7-CART with fully independent intellectual property, targeting the high-unmet need of Relapsed/Refractory T-ALL/LBL.

Asset Materials

Contact Us for Full Materials